Reston, VA (March 28, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Improving Metastatic Breast Cancer Diagnosis with 68Ga-NeoB PET/CT
68Ga-NeoB PET/CT shows promising diagnostic potential for staging metastatic ER/PR-positive and HER2-negative breast cancer, outperforming 18F-FDG PET/CT in some cases. This study highlights its ability to identify disease in patients missed by conventional imaging, suggesting it could enhance breast cancer staging and restaging accuracy.
Enhancing Kidney Safety in Radiopharmaceutical Therapy
Coinfusion of sodium paraaminohippurate with radiopharmaceuticals may reduce kidney toxicity during treatment. Preclinical studies in rats show that paraaminohippurate decreases renal uptake of small radiopharmaceuticals, potentially offering a safer alternative to amino acid infusions, without causing significant side effects or toxicity.
Advancing Dosimetry in Radiopharmaceutical Therapy with Machine Learning
A new "instant" single-time-point (iSTP) dosimetry method uses machine learning to predict the effective half-life of organs, enabling faster and more flexible dosimetry in radiopharmaceutical therapy. This approach reduces the need for strict, late-time imaging, potentially improving the efficiency of treatment in clinical settings.
Improving Response Assessment in GEP-NETs with New Imaging Criteria
Current guidelines for assessing gastroenteropancreatic neuroendocrine tumors (GEP-NETs) under radiopharmaceutical therapy rely on size-based measurements, but functional criteria may offer better accuracy. This study compares RECIST 1.1 with Choi criteria and molecular scores, highlighting their potential in predicting patient progression-free survival and improving response assessment in GEP-NET therapy.
Low Intraprostatic Uptake in PSMA PET/CT for Prostate Cancer
In the proPSMA study, only 3.3 percent of patients with prostate cancer showed low intraprostatic uptake on PSMA PET/CT. Despite this, treatment failure was rare, with most patients receiving definitive therapies like prostatectomy or radiotherapy. These findings suggest that low uptake does not significantly impact long-term outcomes.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
